Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Upgraded by Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of Biodexa Pharmaceuticals stock opened at $2.63 on Friday. Biodexa Pharmaceuticals has a 1 year low of $2.55 and a 1 year high of $92.00. The company’s fifty day simple moving average is $5.24 and its 200-day simple moving average is $6.84.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.